Invivyd's Upcoming Investor Engagements
Invivyd, Inc. (Nasdaq: IVVD), a prominent biopharmaceutical company located in Waltham, is committed to safeguarding against severe viral infections. The company has recently revealed its participation in several key investor conferences, which are designed to engage with stakeholders and share valuable insights into its pioneering research and development efforts.
Key Investor Conferences
Invivyd will connect with investors through a series of fireside chats at notable conferences. Here are the details:
Morgan Stanley 22nd Annual Global Healthcare Conference
The fireside chat is set for this Friday at 10:00 AM ET. This conference gathers leading figures in healthcare, providing an excellent opportunity for Invivyd to highlight its innovative strategies.
H.C. Wainwright 26th Annual Global Investment Conference
On Monday, September 9, 2024, at 9:30 AM ET, Invivyd will take part in this highly attended event, which centers on investment opportunities within the healthcare sector.
2024 Cantor Global Healthcare Conference
This conference is scheduled for Wednesday, September 18, 2024. Invivyd's presentation will begin at 10:55 AM ET and is anticipated to showcase the latest advancements in its monoclonal antibody (mAb) technology.
Webcast Availability
For those who cannot attend, the company will offer live webcasts of the fireside chats on its investor relations website. These sessions will also be archived for approximately 90 days, ensuring broader access to the information shared.
About Invivyd's Innovations
Invivyd has made remarkable progress in the biopharmaceutical field. Its proprietary INVYMAB™ platform is central to its mission of combating viral diseases, especially SARS-CoV-2. With this cutting-edge technology, Invivyd employs advanced viral surveillance and predictive modeling to engineer new monoclonal antibodies that effectively address emerging viral threats.
Recent Achievements
This year, the company received emergency use authorization (EUA) from the U.S. FDA for its first monoclonal antibody, marking a promising path for its future innovations in antibody therapeutics.
Contact Information
If you have any questions or need additional information, please feel free to contact Invivyd's media and investor relations:
Media Relations:
(781) 208-0160
media@invivyd.com
Investor Relations:
(781) 208-0160
investors@invivyd.com
Frequently Asked Questions
What is the focus of Invivyd?
Invivyd is focused on developing solutions that protect against serious viral infectious diseases, primarily through its advanced antibody technology.
When will Invivyd present at the investor conferences?
Invivyd will present at several upcoming conferences, including the Morgan Stanley and H.C. Wainwright conferences, all scheduled for September 2024.
How can I access the live webcasts of the presentations?
The live webcasts will be available on Invivyd's investor relations website, and recordings will be archived for about 90 days after the events.
What technology does Invivyd use for its antibody development?
Invivyd employs its proprietary INVYMAB™ platform, which integrates viral surveillance and predictive modeling with advanced antibody engineering techniques.
Who can I contact for more information about Invivyd?
You can reach out to Invivyd's media relations at (781) 208-0160 or via email at media@invivyd.com for any media inquiries.
